Sign up to save your podcasts
Or
Share Long-term outcomes with pembrolizumab in Hodgkin lymphoma, the “incredible ULK” alleviates β-thalassemia, and recommendations for managing CAR T hematotoxicity
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Long-term outcomes with pembrolizumab in Hodgkin lymphoma, the “incredible ULK” alleviates β-thalassemia, and recommendations for managing CAR T hematotoxicity
In this week's episode, we’ll learn about long-term outcomes with pembrolizumab in relapsed/refractory classical Hodgkin lymphoma. Next, what’s behind the accumulation of toxic free alpha-globin in beta-thalassemia? Finally, a road map for managing CAR T cell hematologic toxicity.
View all episodes
By American Society of Hematology
4.1
4949 ratings
In this week's episode, we’ll learn about long-term outcomes with pembrolizumab in relapsed/refractory classical Hodgkin lymphoma. Next, what’s behind the accumulation of toxic free alpha-globin in beta-thalassemia? Finally, a road map for managing CAR T cell hematologic toxicity.
More shows like Blood Podcast
View all
TED Talks Daily
11,140 Listeners
JAMA Editors' Summary
141 Listeners
NEJM This Week
319 Listeners
JAMA Clinical Reviews
500 Listeners
Hematologic Oncology Update
75 Listeners
The Hematologist
26 Listeners
Core IM | Internal Medicine Podcast
1,156 Listeners
VJHemOnc Podcast
2 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
363 Listeners
The Curious Clinicians
373 Listeners
EHA Unplugged
1 Listeners
Blood Cancer Talks
48 Listeners
Two Onc Docs
190 Listeners
WolverHeme Happy Hour
30 Listeners
HemeTalks: Conversations in Hematology Education
4 Listeners